Use of Dual Antiplatelet Therapy for Acute Ischemic Stroke Increasing

But use of DAPT is also increasing in nonminor stroke patients, who were excluded from the pivotal trials.

Long-term dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is not recommended for secondary stroke prevention due to excess bleeding risk. However, short-term DAPT was shown to reduce early recurrent stroke risk after minor ischemic stroke and transient ischemic attack in the CHANCE and POINT trials, which were reported in 2013 and 2018, respectively. Accordingly, recommendations for short-term DAPT were incorporated in successive revisions of the American Heart Association/American Stroke Association guidelines with progressively higher level-of-evidence classifications from 2011 to 2019. To evaluate how these pivotal trials and guideline updates may have translated into changes in real-world clinical practice, investigators a…

Reviewing Author

Anthony S. Kim, MD

Disclosures

Grant/Research SupportNIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences

Anthony S. Kim, MD

Disclosures

Grant/Research SupportNIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences

Use of Dual Antiplatelet Therapy for Acute Ischemic Stroke Increasing

Topics

Reviewing Author